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Abstract 
 “Acute coronary syndrome (ACS) is a term that encompasses both unstable 
angina and myocardial infarction (MI) with or without ST-segment elevation. “It 
is a life-threatening disorder that remains a source of high morbidity and 
mortality despite advances in treatment. “Risk assessment done by using risk 
factors and risk markers. “One of the emerged risk markers is high circulating 
level of PPAR-γ (a potentially important transcription factor). “This study 
represents a try to evaluate the role of this analyte as a risk biomarker for future 
cardiovascular events, and evaluation of PPAR-γ as a possible diagnostic 
biomarker for MI. “It was a case –control study enrolled 160 subjects; 80 patients 
diagnosed as ACS patients by expert physicians. “An equivalent age and sex 
matched population without coronary disease with similar risk factors considered 
a control group. Serum levels of PPAR-γ were measured by using ELISA 
technique, cTpI was investigated by qualitative membrane- based immunoassay. 
“Independent sample t-test was used to compare means between two groups. 
“ANOVA were used to compare means between different groups, p value ≤ 0.05 is 
significant. “There were significant differences in mean serum levels of PPAR-γ, 
by patients and control. “There was a significant difference in PPAR- γ serum 
levels between positive and negative cTpI groups. “There was an insignificant 
difference in PPAR- γ level among different ECG finding groups. “Circulating 
level of PPAR- γ seems to be used as a risk biomarker for ACS, it is suggested that 
it could be used as a diagnostic biomarker for MI. 
 
 
Journal of University of Babylon for Pure and Applied Sciences,Vol.(26), No.(7): 2018 
011 
 
Introduction 
“The term acute coronary syndrome (ACS) is used to describe the continuum of 
myocardial ischemia (unstable angina pectoris) or infarction (with or without 
concomitant ST segment elevation)[1].“Many large epidemiological studies have 
examined the association between the incidence of coronary artery disease (CAD) 
and a variety of risk factors”. “However, only a small number of risk factors have 
consistently shown an association with increased risk of CAD. Assessment of risk 
factors to identify individuals at high risk for developing CAD plays a central role 
in the strategy of prevention of the disease. “Risk assessment done by using risk 
factors and risk biomarkers[2][3].  
“One of the emerged risk biomarkers is the circulating level of Peroxisome 
proliferator-activated receptor-γ(PPAR-γ). “It is a ligand-dependent transcription 
factor belonging to the nuclear hormone receptor superfamily[4]. “Through its 
role in atherosclerosis and cardiovascular disease it is suggested that its 
circulating level can be used as a predictor to CAD as it is a potentially important 
transcription factor that modulates the inflammatory response of monocytes and 
anti-inflammatory response in other cells[5]. In addition to that its rule in 
ischemia-reperfusion reaction may contribute to its predictive ability [6]. 
“Because the PP-AR-γ gene is expressed in mononuclear phagocytes, which 
respond to hypoxia or ischemia with an exuberant early growth response-1(Egr-
1)-dependent inflammatory response, physiologically, PPAR-γ expression may 
serve as an endogenous mechanism to dampen this pathological response to 
ischemia triggered by zinc finger transcription factor Egr-1 induction[6]. “In 
addition to this role, its presence in cardiomyocytes and atherosclerotic plaque 
[7]may make it a diagnostic biomarker for MI specifically. “This study aimed to 
estimate the significance of PPAR- γ serum levels in ACS patients, and assess 
their predictive ability as risk biomarker. “Investigate the possibility of using 
circulating level of PPAR- γ as a diagnostic biomarker for MI. 
Materials and methods  
Subjects 
Between 1st December 2014and 31stMarch 2015,160 subjects were recruited to 
this study, 80 consecutive patients aged ≥ 40 years old, diagnosed by expert 
physicians to have ACS from coronary care units (CCU) in Merjan Medical City 
and Al-Hilla Teaching Hospital in Babylon Province, Hilla City, in addition to age 
and sex matched (80 subjects) without coronary disease with similar risk factors 
considered as control group. This study was performed in the laboratories of 
Biochemistry Department in collage of Medicine /University of Babylon. The 
overall mean age of patients with ACS and control were (60.28±12.02) and 
(58.21±11.61) years old, respectively. This study was matched for gender, the ratio 
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of male: female was 2:1 for both sexes. ECG changes were estimated by doing 
electrocardiograph by expert nursing staff using apparatus by G.E.Helthcare Co. 
(USA). 
Result: Patients' readings were: ST-elevation 50%, ST-depression 18.7%, T-
inversion 26.3%, and normal ECG 5%. Of them 68.75% presented as MI, and 
31.25% presented as UA.  
Exclusion criteria 
 Patients having the following conditions were excluded: Diabetes mellitus, 
renal failure, patients on hormones, or glucocorticoids regimen, age<40 years, 
patients coming from outside the governorate, pregnant women, incapacity to 
provide informed consent, prior inclusion in the present study, patients with 
known history of thyroid, hepatic, or malignant disease, drug abusers and anemic 
patients.  
Ethical Issues: included  
a- Approval of scientific committee of the Clinical Biochemistry Department in 
Babylon Medical College/ University of Babylon/ Iraq.  
b- Approval of Babylon Health Directorate/Ministry of Health & Information 
Center for Research & Development of Babylon Province.  
c-“The objectives and methodology were explained to all participants in the 
current study and their verbal consent was gained.  
Sample collection:- Five ml of blood were obtained from each subject by vein 
puncture in sitting or lying position, and then pushed slowly into disposable 
tubes containing separating gel. Blood in the gel containing tubes was allowed to 
clot at room temperature for 2 hours and then centrifuged at 1000 ×g for 
approximately 15 minutes, then the supernatant were obtained and stored at -
20˚C until analysis [8]. 
 Materials  
1. Human PPAR-γ ELISA Kit (Elabscience / China)Cat. No.: E-EL-H1361  
2. Human cTnI qualitative membrane- based immunoassay (AbonBiopharma/ 
China) Lot No. CTN 3100076.  
Methods 
PPAR-γ circulating serum level assayed by Elabscience (China) ELISA kit. 
cTnI assayed by using a qualitative membrane- based immunoassay for the 
detection of cTnI in whole blood, serum, or plasma. 
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Statistical analysis 
The collected data were tabulated and analysed by using the Statistical 
Package for Social Sciences (SPSS) for Windows version 20th version. Data were 
expressed as (mean ± SD).Independent sample t-test was used to compare means 
between two groups. Chi square (X2) test and Fisher exact test were used to find 
the significance of the categorical variables. ANOVA were used to compare 
between different groups. P values less than (0.05) were considered significant. 
Results 
a. Differences of Patients with Acute Coronary Syndrome and control 
by Socio-Demographic Characteristics:  
The overall mean age of patients with ACS and control were (60.28±12.02) 
and (58.21±11.61) years old, respectively. There was no significant mean 
difference between the mean age of patients and control. This age matching helps 
to eliminate differences in parameters' results. This study was matched for 
gender, the ratio of male: female was 2:1 for both sexes.  
b. Differences of patients and control by PPAR-γ serum level  
There were significant differences of PPAR-γ serum level by patients and 
control subjects as shown in table (3.1). 
Table (3.1): Mean differences of patients and control by PPAR-γ 
serum level 
 
*p value ≤ 0.05 is significant 
There is a significant mean difference between PPAR-γ serum level and cTnI 
outcomes as a diagnostic biomarker for AMI. (P<0.05) as shown in Table (3.2)  
 
 
 
Variable Group N Mean S.D P value 
PPAR-γ 
case 80 12.78 3.95 
<0.001* 
control 80 3.33 1.81 
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Table (3.2): Mean difference between PPAR-γ serum level and 
different troponin findings. 
 
*P<0.05 is significant 
There is a non-significant difference among different ECG findings of the patients 
and mean PPAR-γ serum level (p>0.05) as shown in table (3.3). 
Table (3.3): Mean difference between PPAR-γ serum level and 
different ECG findings: 
ECG No. Mean 
 
S.D ANOVA p- value 
ST-elevation 40 13.70 4.29 2.064 0.112 
ST-depression 15 12.60 3.50 
T-inversion 21 11.12 3.01 
Normal 4 12.99 4.71 
Total 80 12.78 3.95 
P<0.05 is significant 
Discussion 
Although, PPARγ genotypes considered as modulator factor in CHD risk in 
previous studies [9-12], but there was not any reports regarding to association 
between circulating PPARγ and susceptibility to CHD. “Accordingly, we design 
current study to assess the possible influence of circulating PPARγ on risk 
prediction of CHD. “This study is devoted to analysis of the PPARγ in the 
systemic circulation, but information about the presence of this protein in the 
circulation in human diseases is limited in the literatures according to our 
knowledge.  
“The difference in serum PPAR-γ concentration between controls and ACS 
patients presented in table (3.1) is far greater (mean serum conc. for patients was 
12.75±3.95, while that for control was3.33±1.81) revealed that it is not the 
atherosclerotic background subsided behind it, because patients and control 
subjects were matched in risk factors except history of IHD, “but ischemia-
reperfusion reaction may be the cause as PPAR-γ acts to dampen this reaction 
which is proposed by Abdelrahman M [9] and IvanovaEA[10]. “As the increment 
 cTpI No. Mean S.D t-test p value 
PPAR-γ positive 39 14.26 3.68 3.487 0.001* 
negative 41 11.38 3.71 
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in concentration of PPAR-γ observed in this study seems to be insufficient for 
preventing ischemic events progression in ACS patients as a part of its role as 
anti-inflammatory transcription factor so it is possible that the atherogenic 
effects of PPAR-γ itself may add to the disease, which agree with Ahmadian M et 
al[13], Takano H et al [14], Kapadia R et al [15], Cheng Q et al[16], and Gao X et 
al [17]”.  
“In a pilot study done by Lin Q et al [18] who revealed that PPAR-γ receptor 
protein concentration was negatively correlated with hs-CRP and IL-6 
concentrations. “As ACS patients had high level of inflammatory markers (hs-
CRP and IL-6, etc.) proved by Armstrong EJ et al [19], so it is supposed that 
these patients had low level of PPAR-γ, but as that was not the case, it seems that 
the isoform activated here acts as pro-inflammatory rather than anti-
inflammatory factor, or the increment of serum PPAR-γ concentrations noticed 
in patients may be associated with, activation of its synthesis in tissues, or 
increased its loss by cells. Hence the elevation of PPAR-γ seems to be related 
more to ischemic events rather than the anti-inflammatory/pro-inflammatory 
controversial role in atherosclerosis reported by Takano H et al[12]. 
PPAR-γ as a diagnostic biomarker:- “Patients with either STE- or NSTE- 
AMI have more persistent occlusion of a coronary artery leading to infarction, 
whereas patients with UA have ischemia with either transient or incomplete 
occlusion, so the predictive ability of this marker for MI seems to be related to 
necrosis of myocytes rather than other causes. Cardiac injury resulted in 
releasing of cardiac cells' contents to the circulation in a manner relevant to that 
of cardiac troponins [20]. “The PPAR-γ has an isoform concentrated in cardiac 
cells (PPAR-γ1) as implicated by Azhar S [21], so its significant high serum level 
often may be related to the release of this isoform to the circulation. Another 
source of elevated PPAR-γ may be the necrotic core of the ruptured plaque which 
is a rich source of PPAR-γ4 isoform [21]. “In table (3.3) where it appears that 
PPAR-γ level of 14.26±3.68 accompanied the cases of cTpI +ve, while a level of 
11.38±3.71 accompanied the cases of cTpI –ve. The novelty of our hypothesis is 
that PPAR-γ receptor protein might be a circulating necrosis marker in MI. This 
observation may lead to the probability of using this marker as a diagnostic 
biomarker in the future for MI. “As it was reported by Mehrabia MR et al [22] 
that in addition to its presence in the vasculature, PPAR-γ is also expressed in 
adult human hearts, where the transcription factor might regulate metabolic 
events important for cell survival and induction of growth.Mehrabia MR et al 
[22] showed that PPAR-γ expression is higher in normal left ventricles compared 
to the aorta and coronary arteries. “In contrast to the results from healthy 
specimens, it was found that higher PPAR-γ levels in the coronary arteries of 
both coronary heart disease (CHD) and dilated cardio-myopathic (CMP) patients, 
compared to the aorta. “Therefore, it was speculated that PPAR-γ is up-regulated 
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in coronary arteries of CHD and CMP patients. “This might be explained partly 
by atherosclerotic lesions in the vessel wall, which highly express PPAR-γ. “The 
observation of this study[22] lead us to a suggestion that high serum level of 
PPAR-γ seen in the present study in MI patients significantly is related more to 
necrotic myocytes which had primarily high expression of PPAR-γ in addition to 
atherosclerotic plaque ruptured in coronary arteries enriched with this 
transcription factor. “To our knowledge, no other publications have suggested 
this possibility.  
“The non-significant difference between PPAR-γ serum level and different ECG 
outcomes presented in table (3.4) revealed inability of using this analyte to 
differentiate between different anatomic infarcted sites in myocardium as it was 
presented by ECG. “But it seems clearly from table (3.4) that the highest PPAR-γ 
serum level accompanied the ST-elevation cases which represent transmural 
(full-thickness) MI that is associated with atherosclerosis involving a major 
coronary artery[20]. “In ST-segment depression and T-wave inversion groups 
which accompanied with lowest levels of PPAR-γ as noticed in table (3.4), there is 
partial occlusion of a major vessel or complete occlusion of a minor vessel, 
causing unstable angina or partial-thickness (subendocardial) MI [20]. “This 
observation strengthen our suggestion about the source of circulating PPAR-γ 
noticed in the present study which may be mostly due to larger infarct size of the 
heart muscle rather than the ruptured plaque. “The understanding of the role of 
PPAR-γ in ACS gives promise for more forthcoming progress in this field and can 
be used to quantify risk and to guide preventive care in addition to its suggestive 
value as a diagnostic biomarker”. 
Conclusion 
PPAR-γ represents a risk biomarker of M.I. in ACS patients among the other 
biomarkers. There is a possibility that circulating level of PPAR-γ to be a project 
of diagnostic biomarker for MI in addition to its predictive ability. 
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